*.- El Mesothelioma Maligno es una Enfermedad Agresiva con pronóstico Sombrío a pesar del Tratamiento Multimodal incluyendo la Quimioterapia, Cirugía y Radioterapia. *.- En la progresión es posible proporcionar un tratamiento de segunda línea del sistema, pero sus efectos son limitados.
*.- Desde el Department of Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland nos presentan dos casos de Pacientes con Mesothelioma que recibieron Quimioterapia de segunda línea con la combinación de Cisplatino y Lurbinectedin .
*.- La Combinación Mostró Actividad Prometedora en ambos casos con Toxicidad Manejable.
Combination of Cisplatin and Lurbinectedin as Palliative Chemotherapy in Progressive Malignant Pleural Mesothelioma : Report of two cases .Yannis Metaxas, MD, Richard Cathomas, Michael Mark, Roger von Moos .
Department of Oncology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland .
Highlights :
•Most malignant mesotheliomas are not curable despite multimodal treatment.
•Treatment with cisplatin and the novel compound lurbinectedin seems promising.
•The course of two cases is presented.
Abstract :
Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. At progression it is possible to provide systemic second-line treatment but its effects are limited. Herein we report two patient cases with mesothelioma who received second-line chemotherapy with the combination of cisplatin and the novel compound lurbinectedin. The combination showed promising activity in both cases with manageable toxicity. We discuss the results of this regime in the light of historical as well as emerging data in Mesothelioma.
Publication stage: In Press Accepted Manuscript .
Published online: July 13 2016 .
© 2016 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
